montelukast + bepotastine

montelukast + bepotastine is a **combination pharmaceutical formulation** containing both montelukast sodium and bepotastine besilate. It is developed primarily for the **management of allergic rhinitis and asthma**. - **Montelukast** is a leukotriene receptor antagonist, selectively blocking cysteinyl leukotriene receptor 1 (CysLT1) to reduce airway inflammation, bronchoconstriction, and allergic symptoms. - **Bepotastine** is a second-generation antihistamine, acting as a selective antagonist of the histamine H1 receptor, with additional mast cell stabilizing effects and inhibition of eosinophil migration, thus decreasing allergic inflammation. The formulation described utilizes a **multilayer, gastro-retentive tablet design**, with montelukast in the immediate-release layer and bepotastine in both immediate- and sustained-release layers, optimizing release rates, drug absorption, and duration of action for once-daily dosing[1][5][7]. This combination targets complementary allergic and inflammatory pathways for improved symptom control and patient adherence, especially when asthma and allergic rhinitis coexist.

Other names

montelukast + bepotastinemontelukast sodium + bepotastine besilate